Nivolumab gets FDA approval for those at high risk of recurrence after surgery
Source: PD-1 Inhibitor OK’d as Adjuvant Therapy for Bladder Cancer | MedPage Today
Nivolumab gets FDA approval for those at high risk of recurrence after surgery
Source: PD-1 Inhibitor OK’d as Adjuvant Therapy for Bladder Cancer | MedPage Today
LET US PROVIDE YOU WITH THE LATEST MEDICAL NEWS, NETWORKING AND PROFESSIONAL DEVELOPMENT OPPORTUNITIES, AND EXCITING JOB OPENINGS FOR RADIOLOGISTS.
"*" indicates required fields
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.
Our team will contact you soon.

